- $5.11bn
- $7.45bn
- $1.49bn
Archrock Inc reports results for the quarter ended June 30 - Earnings Summary
Archrock Q2 results miss estimates on cost pressures
Brief: Archrock Q2 Adjusted EBITDA USD 212.6 Million Vs. IBES Estimate USD 221.9 Million
Brief: Archrock Increases Quarterly Cash Dividend
Archrock Q1 revenue rises but misses estimates, EBITDA beats
Brief: Archrock Q1 Adjusted EBITDA USD 221 Million Vs. IBES Estimate USD 216.6 Million
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
Gas compression services firm Archrock's Q4 revenue slightly misses estimates
Brief: Archrock Q4 Adjusted EBITDA USD 269.4 Million Vs. IBES Estimate USD 210.9 Million
Brief: Archrock Announces Closing Of $800 Million Of Senior Notes Offering
Brief: Archrock Announces Upsizing and Pricing of $800 Million of Senior Notes
Brief: Archrock Enters Third Amendment To Credit Agreement
NatGas compression services provider Archrock Q3 revenue beats estimates, raises FY adj EBITDA guidance
Brief: Archrock Q3 Adjusted EBITDA USD 220.9 Million Vs. IBES Estimate USD 208.4 Million
Brief: Archrock Files For Mixed Shelf; Size Not Disclosed- SEC Filing
Archrock Inc reports results for the quarter ended June 30 - Earnings Summary
Archrock's Q2 revenue rises, beats analyst estimates
Archrock Inc expected to post earnings of 37 cents a share - Earnings Preview
Archrock Inc reports results for the quarter ended March 31 - Earnings Summary